Recombinant Human Granulocyte/Macrophage Colonystimulating Factor（rhGM-CSF）
- Generic Name
- Recombinant Human Granulocyte/Macrophage Colonystimulating Factor（rhGM-CSF）
- Indication
用于：1.恶性肿瘤、白血病化、放疗引起的白血病减少及其并发的感染；
2.造血干/祖细胞移植后髓系造血功能受抑及延迟植活与移植排斥；
3.与rhG-CSF等造血生长因子联合或单独应用于外周血造血干/祖细胞移植前的干/祖细胞动员；
4.再生障碍性贫血等骨髓衰竭性疾患及各种严重感染并发的中性粒细胞减少；
5.也可用于艾滋病本身、或因药物治疗所致的中性粒细胞减少。
Naxitamab for High-Risk Neuroblastoma Patients with Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone And/or Bone Marrow
- First Posted Date
- 2017-12-06
- Last Posted Date
- 2025-02-20
- Lead Sponsor
- Y-mAbs Therapeutics
- Target Recruit Count
- 122
- Registration Number
- NCT03363373
- Locations
- 🇬🇧
University Hospital Southampton, Southampton, United Kingdom
🇺🇸University of Florida, Gainesville, Florida, United States
🇺🇸University of Chicago, Chicago, Illinois, United States
Sequential Therapy With WLL/Inhaling GM-CSF for Autoimmune Pulmonary Alveolar Proteinosis
- First Posted Date
- 2017-10-20
- Last Posted Date
- 2017-10-20
- Lead Sponsor
- Dai Huaping
- Target Recruit Count
- 60
- Registration Number
- NCT03316651
- Locations
- 🇨🇳
China Japan Friendship Hispital, Beijing, China
Granulocyte-Macrophage Stimulating Factor (GM-CSF) in Peripheral Arterial Disease
- First Posted Date
- 2017-10-09
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Emory University
- Target Recruit Count
- 176
- Registration Number
- NCT03304821
- Locations
- 🇺🇸
Emory University Hospital, Atlanta, Georgia, United States
REO13 Melanoma With of Without GM-CSF
- First Posted Date
- 2017-09-13
- Last Posted Date
- 2018-05-04
- Lead Sponsor
- University of Leeds
- Registration Number
- NCT03282188
Phase II Trial of FOLFOXIGIL Versus FOLFOXIRI as First-line Therapy in Patients With mCRC
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- First Posted Date
- 2017-07-19
- Last Posted Date
- 2018-03-27
- Lead Sponsor
- Fujian Cancer Hospital
- Registration Number
- NCT03222089
- Locations
- 🇨🇳
Rongbo Lin, Fuzhou, Fujian, China
Study of Chemoimmunotherapy for High-Risk Neuroblastoma
- Conditions
- Neuroblastoma (NB)
- Interventions
- First Posted Date
- 2017-06-16
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 48
- Registration Number
- NCT03189706
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
A Study of the Effect of Hu3F8/GM-CSF Immunotherapy Plus Isotretinoin in Patients in First Remission of High-Risk Neuroblastoma
- Conditions
- Neuroblastoma
- Interventions
- First Posted Date
- 2017-01-26
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 59
- Registration Number
- NCT03033303
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Dendritic Cell/Myeloma Fusion Vaccine for Multiple Myeloma (BMT CTN 1401)
- Conditions
- Multiple Myeloma
- Interventions
- Procedure: Tumor Cell CollectionProcedure: Autologous Stem Cell TransplantProcedure: LeukapheresisBiological: Myeloma vaccine
- First Posted Date
- 2016-04-05
- Last Posted Date
- 2024-05-07
- Target Recruit Count
- 203
- Registration Number
- NCT02728102
- Locations
- 🇺🇸
University of Maryland/Greenebaum Cancer Center, Baltimore, Maryland, United States
🇺🇸Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
🇺🇸University of Wisconsin Hospital & Clinics, Madison, Wisconsin, United States
NB2013-HR German (GPOH) / Dutch (DCOG) Trial
- Conditions
- Neuroblastoma
- Interventions
- First Posted Date
- 2015-12-29
- Last Posted Date
- 2022-11-04
- Lead Sponsor
- University of Cologne
- Target Recruit Count
- 3
- Registration Number
- NCT02641782
- Locations
- 🇩🇪
University of Cologne, Cologne, Germany
Humanized Monoclonal Antibody 3F8 (Hu3F8) With Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in the Treatment of Recurrent Osteosarcoma
- Conditions
- Recurrent Osteosarcoma
- Interventions
- Biological: humanized anti-GD2 antibody
- First Posted Date
- 2015-07-20
- Last Posted Date
- 2024-10-29
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 46
- Registration Number
- NCT02502786
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸Children's Hospital of Los Angeles (Data Collection Only), Los Angeles, California, United States
🇺🇸MD ANDERSON CANCER CENTER (Data Collection Only), Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.